Correa-González LC, Mandeville PB, Manrique-Dueñas J, Alejo-González F, Salazar-Martínez A, Pérez-Ramírez OJ, Hernández-Sierra JF.

Idioma: Español
Referencias bibliográficas: 55
Paginas: 477-482
Archivo PDF: 49.88 Kb.

RESUMEN

Objetivo: Determinar el valor pronóstico del inmunofenotipo pre-B con sus variantes en la respuesta temprana al tratamiento de la leucemia aguda linfoblástica pediátrica, ajustando edad y cifra de leucocitos inicial.
Pacientes y método: Se realizó un estudio de casos y controles anidado en una cohorte con pacientes menores de 15 años de edad, de los dos géneros, con leucemia aguda linfoblástica pre-B de diagnóstico reciente. Se utilizó un panel de anticuerpos monoclonales específicos de la estirpe B, T, monocito-mielocito y megacariocítica. Se evaluó la respuesta después de 14 días de tratamiento mediante aspirado de médula ósea.
Resultados: Se incluyeron 54 pacientes. La mediana de edad fue de 7 años (2m-14 años), la mediana de cifra de leucocitos fue 13,450/mm³ (1200-986,000/mm³). Se identificaron 29 casos con inmunofenotipo Pre-B tardío, 19 casos pre-B común y 6 casos de pre-B precoz. Once pacientes presentaron antígenos mieloides asociados. Se encontró asociación significativa (p=0.034) entre respuesta temprana y la presencia de antígenos mieloides. No se demostró asociación entre las variantes del inmuno-fenotipo pre-B, edad y cifra de leucocitos con la respuesta temprana (p=0.264).
Conclusiones: Es necesario estudiar directamente la respuesta tem-prana al tratamiento en los niños con leucemia linfoblástica ya que en nuestra muestra de pacientes los factores clínicos y el inmunofenotipo no fueron predictivos de ésta.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Fajardo-Gutiérrez A, Mendoza Sánchez H, Valdez Martínez E, y cols. Frecuencia de neoplasias malignas en niños atendidos en hospitales del Distrito Federal. Estudio Multicéntrico. Bol Med Hosp Infant Mex 1996;53:57-66.

2. 2. Fajardo-Gutiérrez A, Mejía Aranguré M, Juárez Ocaña S. El cáncer, un problema de salud que incrementa en el niño. Un reto para conocer su epidemiología en los niños mexicanos. Bol Med Hosp Infant Mex 2001;58:721-742.

3. 3. Margolin JF, Steuber ChP, Poplack DG. Acute Lymphoblastic Leukemia. En Principles and Practice of Pediatric Oncology. Pizzo PA, Poplack DG (Eds) JP Lippincott Co. 4a ed. Philadelphia, 2002. p. 431-481.

4. 4. Pui CH. Childhood leukemias. N Engl J Med 1995;332:1618-1630.

5. 5. Kersey JH. Fifty Years of studies of the biology and therapy of childhood leukemia. Blood 1997;90:4243-4251.

6. 6. Romero F, Paredes R. Definición de riesgos en Leucemia Aguda, de acuerdo a la clasificación. En Actualización en Leucemias. Ruiz Argüelles GJ., San Miguel JF (eds). Editorial Médica Panamericana. México DF. 1996. p. 41-49.

7. 7. Advani S, Pai S, Venzon D et al. Acute Lymphoblastic Leukemia in India: An analysis of prognostic factors using a single treatment regimen. Ann Oncol 1999;10:167-176.

8. 8. Sallan SE, Ritz J, Pesandro J. Cells Surface antigens: Prognostic implications in childhood acute Lymphoblastic Leukemia. Blood 1980;55:395.

9. 9. Donadieu J, Auclerc MF, Baruchel A, et al. Critical study of prognostic factors in childhood acute Lymphoblatic Leukemia; differences in outcome are poorly explained by the most significant Prognostic variables. Br J Hemat 1998;102: 729-739.

10. Pui CH. Acute Lymphoblastic leukemia in children. Current opinion in Oncology 2000;12:3-12.

11. Miller DR, Leikin S, Albo V, et al. Prognostic factors and therapy in acute lymphoblastic leukemia of childhood: CCG-141: A report from the Childrens Cancer Study Group. Cancer 1983;51:1041-1049.

12. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignement for children with ALL. J Clin Oncol 1996;14:18-24.

13. Pui CH, Boyett JM, Relling MV, et al. Sex differences in prognosis for children with acute lymphoblastic leukemia. J Clin Oncol 1999,17:818-824.

14. Catovsky D. Clasificación de la leucemia linfoblástica aguda. En Enciclopedia Iberoamericana de Hematología. López Borrasca A, Arocha Pinango CL., Campos Guerra C (Eds). Ediciones Universidad de Salamanca. 1ª. Edición. Salamanca, España, 1992. p. 258-264.

15. Paredes Aguilera R, Romero Guzmán L, López Santiago N. y cols Inmunofenotipo de la leucemia aguda linfoblástica en niños mexicanos. Sangre 1999;44:188-194.

16. San Miguel JF, Duque R. Utilidad del inmunofenotipo en el diagnóstico y clasificación de las leucemias agudas. En Actualización en leucemias. Ruiz Argüelles GJ, San Miguel JF (eds) Ed Médica Panamericana 1ª ed. México, DF. 1996. p. 25-34.

17. Paietta E, Andersen J, Wiernik PH, et al. A New approach to analyzing the utility of immunophenotyping for predicting clinical outcome in acute leukemia. Leukemia 1996;10:l-4.

18. Crist W, Boyett J, Jackson J, et al. Prognostic importance of the Pre-B-Cell Immunophenotype and other presenting features in B lineage Childhood Acute Lymphoblastic Leukemia: A Pediatric Oncology Group Study. Blood 1995;74: 1252-1259.

19. Reiter A, Schrape M, Tiemann M, et al. Improved Treatment Results in Childhood B-Cell Neoplasm With Tailored Intensification of Therapy: A Report of the Berlin-Frankfurt-Münster Group Trial NHL-BFM 90. Blood 1999;94:3294-3306.

20. Greaves MF, Janossy G, Peto J, et al. Immunologically Defined subclasses of Acute Lymphoblastic Leukaemia in Children: their relationship to presentation features and prognosis. Br J Haematol 1981;48:179-197.

21. Crist W, Boyett J, Roper M, et al. Pre-B Cell leukemia responds poorly to treatment: A Pediatric Oncology Group Study. Blood 1984;63:407-414.

22. Pui CH, Rubnitz JE, Hancock ML, et al. Reappraisal of the clinical and biologic significance of myeloid associated antigen expression in childhood acute lymphoblastic leukemia. J Clin Oncol 1998;16:3766-3773.

23. Putti MC, Rondelli R, Cocito MG, et al. Expression of myeloid markers lacks prognostic impact in children treated for acute lymphoblastic leukemia: Italian experience in AIEOP-ALL 88-91 studies. Blood 1998;92:795-801.

24. Khalidi HS, Chang KL, Medeiros LJ, et al. Acute Lymphoblastic leukemia. Survey of immunophenotype, French-American-British classification, frecuency of myeloid antigen expression and karyotypic abnormalities in 210 pediatric and adult cases. Am J Clin Pathol 1999;111: 467-76.

25. Wiersma SR, Ortega J, Sobel E, et al. Clinical importance of myeloid antigen expression in Acute lymphoblastic leukemia of Childhood. N Engl J Med 1991;324:800-808.

26. Kurec AS, Belair P, Stefanu C, et al. Significance of aberrant inmunophenotypes in childhood acute lymphoblastic leukemia. Cancer 1991;67:3081-3086.

27. Cantu-Rajnoidi A, Putti C, Saitta M, et al. Co-expression of myeloid antigens in childhood acute lymphoblastic leukaemia: Relationship with the stage of differentiation and clinical significance. Br J Haematol 1991;79:40-43.

28. Pui CH, Behm FG, Singh B, et al. Myeloid-associated antigen expression lacks prognostic value in childhood acute lymphoblastic leukemia treated with intensive multiagent chemotherapy. Blood 1990;75:198-202.

29. Pui CH, Schell MJ, Raimondi SC, et al. Myeloid-antigen expression in childhood acute lymphoblastic leukemia. N Engl J Med 1991;325:1378-179.

30. Pui CH, Raimondi SC, Head DR, et al. Characterization of childhood acute leukemia with multiple myeloid and lymphoid markers at diagnosis and at relapse. Blood 1991;78:1327-1337.

31. Griffin TC, Shuster JJ, Buchanan GR, et al. Slow reduction of periferal blood blast count is an adverse prognostic factor in childhood T-Cell Acute Lymphoblastic Leukemia (T-ALL): A Pediatric Oncology Group study. Thirty-fourth Annual Meeting (2025) Proceedings ASCO 1998. p. 527.

32. Brisco MJ, Sykes PJ, Hughes E, et al. Monitoring minimal residual disease in peripheral blood in B lineage acute lymphoblastic leukaemia. Br J Haematol 1997;99:314-319.

33. Silverman LB, Gelber RD, Young ML, et al. Induction failure in acute Lymphoblastic leukemia of childhood. Cancer 1999; 85: 1395- 1404.

34. Miller DR, Coccia PF, Bleyer WA, et al. Early response to induction therapy predicts disease-free survival and late recurrence of childhood acute lymphoblastic leukemia: A report form the Children's Cancer Study Group. Blood 68 (5, Suppl1):227 a, 1986-abstract #786.

35. Steinherz PG, Gaynon PS, Breneman JC, et al. Cytoreduction and prognosis in Acute Lymphoblastic Leukemia. The importance of Early Marrow Response: Report From the Childrens Cancer Group. J Clin Oncol 1996;14:389-398.

36. Frei E, Sallan SE. Acute Lymphoblastic leukemia, treatment. Cancer 1978;42:828-838.

37. Rivera GK, Raimondi SC, Hancock MI, et al. Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment with rotational combination chemotherapy. Lancet 1991;337:61-66.

38. Hann IM, Vora AJ, Harrison G, et al. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia-results from MRC UKALL XI. Br J Haematol 2001;113:103-114.

39. Hernández H D, Garduño Espinoza J, Hernández Sierra JF, y cols. Clasificación en niveles de los diseños de investigación clínico epidemiológicas. Rev Invest Clin 1998;50:79-86.

40. Bennett JM, Catovsky D, Daniel MT, et al. French- American- British (FAB) Cooperative Group: The morphological classification of Acute Lymphoblastic Leukemia. Concordance among observers and clinical correlations. Br J Haematol 1981;47:553.

41. Miller DR, Leikin S, Albo V, et al. Prognostic Importance of Morphology (FAB Classification) in Childhood Acute Lymphoblastic Leukaemia (ALL). A report from Childrens Cancer Study Group. Br J Haematol 1981;48:199-206.

42. Mc Keena RW, Brynes RK, Nesbit ME, et al. Cytochemical profiles in acute lymphoblastic Leukemia. Am J Pediatr Hematol-Oncol 1979;l:263-275.

43. Fajardo GA, Yamamoto KL, Garduño EJ, Hernández HD. y cols. Consistencia y validez de una medición en la investigación clínica pediátrica. Definición, evaluación y su interpretación. Bol Med Hosp Infant Mex 1991;48:367-376.

44. Feinstein AR. Clinical Epidemiology. The architecture of clinical research. W B Saunders Co. 1985.

45. Ihaka R, Gentleman R. A language for data analysis and graphics. Journal of computational and graphical statistics 1996;5:299-314.

46. Shapiro SS, Wilk MB. An analysis of variance test for normality (complete samples). Biometrika 1965;52:591-611.

47. Conover WJ, Johnson ME, Johnson MM. A comparative study of test for homogeneity of variances, with applications to the outer continental shelf bidding data. Technometrics 1981;23:351-161.

48. Venables WN, Ripley BD. Modern applied statistics with s-plus. In statistics and computing. Venables ed. 4a edition 2002. New York N.Y.

49. Burnham KP, Anderson DR. Model selection and multimodel inference: a practical information-theoretic approach. In Springer-Verlag eds.2a edition 2002. New York, N.Y

50. Foon KA, Tood RF, Inmunologic classification of leukemia and lymphoma. Blood 1986;68:1-31.

51. Paredes Aguilera R, Romero Guzmán L, López Santiago N. Flow Cytometric Analysis of Cell-surface and intracellular antigens in the diagnosis of Acute Leukemia. Am J Hematol 2001;68:69-74.

52. Uckun FM, Sather HN, Gaynon PS, et al. Clinical features and treatment outcome of children with myeloid antigen positive acute lymphoblastic leukemia: A report from Children’s Cancer Group. Blood 1997;90: 28-35.

53. Ng SM, Ariffin WA, Lin HP, et al. Clinical features and treatment outcome of children with myeloid antigen coexpression in B-lineage acute lymphoblastic leukemia: a study of 151 Malaysian children. J Trop Pediatr 2000;46:73-78.

54. Urbano Ispizua A, Matutes E, Villamor N, y cols. Clinical significance of the presence of myeloid associated antigens in acute lymphoblastic leukaemia. Br J Haematol 1990;75:202-207.

55. Lindman HR. Analysis of variance, One-way, Fixed effects. In Analysis of variance in experimental design. Springer – Verlag. New York. 1992. p. 20-37.